Latest Breaking News On - Mary lynne hedley - Page 4 : comparemela.com

Helsinn Healthcare S.A.: Helsinn appoints Mary Lynne Hedley to Board of Directors 20 21 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne Hedley as a new member of its Board of Directors, effective April 28, 2021. Dr. Hedley is an immunologist and cancer cell biologist, with a vast level of experience within the pharmaceutical industry, specifically within the field of oncology. Most recently, Dr Hedley was Director, President and Chief Operating Officer at TESARO, a biotechnology company she co-founded in 2010, focused on the development and global commercialization of oncology therapeutics. During her time at TESARO the team built up a pipeline of early and late stage drug candidates including the commercial product niraparib, a PARP inhibitor that changed the treatment paradigm for women diagnosed with ovarian cancer. The company was acquired by GlaxoSmithKline in

United statesPaola bonviciniRiccardo bragliaMary lynne hedleyPurdue universityHelsinn group viceSwiss pharma companyAbraxis bioscienceHarvard universityHelsinn group media contactB future health fundHelsinn groupIreland helsinn birex pharmaceuticalsHelsinn investment fundEisai incChina helsinn pharmaceuticals